Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00899860 · ClinicalTrials.gov registry record
Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- 30
- Enrollment target
NCT00899860: Clinical Trial study, sponsored by Wake Forest University Health Sciences.
NCT00899860 is a clinical trial that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00899860 was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Studying the genes and proteins expressed in tissue samples from patients with cancer may help doctors identify biomarkers related to cancer. PURPOSE: This laboratory study is evaluating gene and protein expression in normal tissue and tumor tissue from patients who have undergone surgery for kidney cancer.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-09 |
| Est. Completion | 2012-06 |
Why NCT00899860 stopped before completion
NCT00899860 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00899860 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00899860 about?
NCT00899860 is a clinical study titled "Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer". RATIONALE: Studying the genes and proteins expressed in tissue samples from patients with cancer may help doctors identify biomarkers related to cancer. PURPOSE: This laboratory study is evaluating gene and protein expression in normal tissue and tumor tissue from patients who have undergone surger...
What is the current status of trial NCT00899860?
This trial is currently terminated. The enrollment target is 30 participants. The study started on 2003-09. Estimated completion is 2012-06.
Who is sponsoring clinical trial NCT00899860?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia